<DOC>
	<DOCNO>NCT00003434</DOCNO>
	<brief_summary>Rational : White blood cell treat carcinoembryonic antigen peptide-1 may help body build immune response kill tumor cell express CEA . Purpose : Phase II trial study effectiveness white blood cell plus carcinoembryonic antigen peptide-1 treating patient stage I , stage II , stage III pancreatic cancer surgically remove .</brief_summary>
	<brief_title>Biological Therapy Stage I , Stage II , Stage III Surgically Resected Pancreatic Cancer</brief_title>
	<detailed_description>Objective : I . Perform pilot study active immunotherapy autologous dendritic cell pulse CEA peptide , CAP-1 , surgical resection patient CEA express pancreatic cancer . II . Perform laboratory analysis monitor presence , persistence , function CAP-1 specific T-cells patient population . Outline : Patients undergo leukapheresis 4.5 hour prior vaccination . Half collect dendritic cell pulse carcinoembryonic antigen ( CEA ) peptide half pulse hepatitis B antigen peptide ( HBsAg ) . Equal dos CEA HBsAg peptide pulse dendritic cell administer intravenously 3 minute every 4 week total 6 dos . Patients undergo second leukopheresis 2 week last dose immunotherapy obtain specimens immunologic test . Patients follow week 22 , 36 , 48 , every 6 month thereafter . Project Accrual : A total 24 patient accrue study 2 year .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Disease Characteristics : Histologically confirm stage I , II , III adenocarcinoma pancreas Resected gross residual disease At least 50 % tumor cell must CEA positive stain least moderate intensity HLAA2 positive Patient Characteristics : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Greater 6 month Hematopoietic : Absolute neutrophil count least 1000/mm3 Hepatic : Bilirubin le 2.0 mg/dL SGOT alkaline phosphatase less 4 time upper limit normal No hepatic failure Renal : Creatinine le 2.0 mg/dL OR Creatinine clearance great 50 mL/min Cardiovascular : No New York Heart Association class III IV heart disease Pulmonary : No concurrent asthma chronic obstructive pulmonary disease Other : No malignancy except nonmelanoma skin cancer control superficial bladder cancer within past 5 year . No history autoimmune diseases inflammatory bowel disease , systemic lupus erythematosus , ankylose spondylitis , scleroderma , rheumatoid arthritis , multiple sclerosis No active acute chronic infection urinary tract infection , HIV , viral hepatitis No active infectious enteritis eosinophilic enteritis Not pregnant nursing Fertile patient must use effective contraception Prior Therapy : Biologic therapy : At least 4 week since immunotherapy . No concurrent immunotherapy Chemotherapy : At least 4 week since chemotherapy recover . No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroid immunosuppressive therapy . At least 6 week since steroid therapy Radiotherapy : At least 4 week since radiotherapy recover Surgery : Recovered prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>